Swedish Orphan Biovitrum has announced an agreement with Amgen to run an additional Kineret bulk drug campaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previously agreed future sales milestones for Kineret and Kepivance.
Under the agreement Amgen will run an additional Kineret campaign at its Boulder facility in Colorado, as well as manufacture drug product at its facility in Puerto Rico. The objective of this additional campaign is to meet an expected increased market demand of Kineret until Swedish Orphan Biovitrum has transferred manufacturing processes to new contract manufacturers.
"We have with great excitement noticed an increased demand for Kineret@ throughout 2009. Hence we are happy that Amgen will run an additional Kineret campaign as we continue our efforts to provide our innovative drug to patients who need it," said Martin Nicklasson, CEO of Biovitrum.